|
18/02/2012
|
|
EMA: Aprotinin Gets Restricted OK; Orlistat Safe Despite Liver Reports
|
|
The European Medicines Agency announced Feb. 17 that it was recommending lifting the 4-year-old suspension of aprotinin, a medicine used to prevent blood loss.The agency recommended that the marketing...
|
|
|
16/02/2012
|
|
Pancreatic Cancer Risk Not Confined to IPMN Target Cyst
|
|
SAN FRANCISCO (EGMN) – A small proportion of patients with a lower-risk intraductal papillary mucinous neoplasm go on to develop pancreatic ductal adenocarcinoma in an entirely separate region of the ...
|
|
|
14/02/2012
|
|
Lynch Syndrome Linked to Breast, Pancreatic Cancers
|
|
A prospective study has confirmed that Lynch syndrome, an inherited disorder that predisposes to many types of cancer, significantly raises the risk of both breast cancer and pancreatic cancer. The tr...
|
|
|
11/02/2012
|
|
Accelerated Decrease in HBsAg Seen Before HBV Clearance
|
|
Serum hepatitis B surface antigen (HBsAg) seroclearance is preceded by significant, accelerated decreases in serum HBsAg levels during the 3 years leading up to seroclearance, wrote Dr. Yi-Cheng Chen ...
|
|
|
07/02/2012
|
|
EDEN Trial Questions Restricting Nutrition to ALI Patients
|
|
HOUSTON (EGMN) – Restricting the amount of initial enteral intake in mechanically ventilated patients who have acute lung injury neither reduces the duration of mechanical ventilation nor improves mor...
|
|
|
03/02/2012
|
|
Gene Signature Predicts Response to Esophagogastric Cancer Therapy
|
|
SAN FRANCISCO (EGMN)–A new 86-gene signature may add to metabolic imaging in guiding early treatment decisions for esophagogastric junction cancer, researchers reported.The leptin gene, among others, ...
|
|
|
02/02/2012
|
|
FDA Adds Longer GIST Therapy to Imatinib Label
|
|
Clinical trial data showing a significant increase in survival when imatinib is used for 3 years as adjuvant therapy after resection of Kit-positive gastrointestinal stromal tumors has been added to t...
|
|
|
01/02/2012
|
|
Metformin May Lower Pancreatic Cancer Risk in Women
|
|
Metformin use was associated with a decreased risk of pancreatic cancer in women, but not in men, in a large case-control study involving more than 19,300 U.K. primary care patients.Additionally, use ...
|
|
|
31/01/2012
|
|
Regorafenib Prolongs Survival After Colorectal Cancer Therapies Fail
|
|
SAN FRANCISCO (EGMN) – Adding the oral, investigational multikinase inhibitor regorafenib to best supportive care for metastatic colorectal cancer resulted in a modest but statistically significant in...
|
|
|
28/01/2012
|
|
CORRECTION: Lansoprazole Disappoints for Poorly Controlled Asthma in Kids
|
|
An article titled “Lansoprazole Disappoints for Poorly Controlled Asthma in Kids,” published January 24, 2012, used an incorrect pronoun when referring to Dr. Nicola Hanania.
|
|
|
28/01/2012
|
|
Brivanib Disappoints in KRAS Wild-Type Colorectal Cancer
|
|
SAN FRANCISCO (EGMN) – Eagerly awaited results of the CO.20 trial in metastatic chemorefractory KRAS wild-type colorectal cancer are disappointing, showing no significant gain in the primary end point...
|
|
|
26/01/2012
|
|
Gastric Cancer Subtype May Affect Bevacizumab Benefit
|
|
SAN FRANCISCO (EGMN) – The benefit of bevacizumab in some patients with advanced gastric cancer appears to vary by disease subtype, based on an exploratory analysis of data from the phase III AVAGAST ...
|
|
|
25/01/2012
|
|
NICE Nixes Bevacizumab, Cetuximab, and Panitumumab in Colorectal Cancer
|
|
The cost-effectiveness institute for England and Wales has rejected three biological treatments for metastatic colorectal cancer that has progressed after initial or second-line treatment.The National...
|
|
|
25/01/2012
|
|
Lansoprazole Disappoints for Poorly Controlled Asthma in Kids
|
|
The proton pump inhibitor lansoprazole was no better than placebo for improving symptoms and lung function in a randomized, placebo-controlled trial involving more than 300 children with poorly contro...
|
|
|
25/01/2012
|
|
No Panitumumab Benefit Seen in Colorectal Cancer with KRAS Mutations
|
|
SAN FRANCISCO (EGMN) – None of the common KRAS mutant alleles seen in metastatic colorectal cancer reliably predict benefit from panitumumab, new data show, suggesting that this agent should continue ...
|
|
|
24/01/2012
|
|
New Risk Factor Identified for PML With Natalizumab
|
|
The U.S. Food and Drug Administration has identified a new risk factor for progressive multifocal leukoencephalopathy, a life-threatening brain infection associated with the use of natalizumab, an imm...
|
|
|
19/01/2012
|
|
Regorafenib Anticipated to Show Survival Advantage in Colorectal Cancer
|
|
Phase III data on regorafenib, the first small-molecule kinase inhibitor to demonstrate a significant survival advantage in colorectal cancer, will be presented at the American Society of Clinical Onc...
|
|
|
18/01/2012
|
|
Weight Loss Higher After Roux-en-Y Surgery vs. Gastric Banding
|
|
Roux-en-Y gastric bypass surgery resulted in greater, more rapid, and more sustained weight loss compared with gastric banding, but also a higher number of complications in a matched-pair study publis...
|
|
|
12/01/2012
|
|
Geography Linked to IBD Incidence in Women
|
|
Geographic location could be associated with incidence of inflammatory bowel disease, based on a new study showing that women living in southern portions of the United States had a lower incidence tha...
|
|
|
12/01/2012
|
|
Seizure Increase Not Seen Following Gastric Bypass
|
|
BALTIMORE (EGMN)–No notable increases in new-onset seizure disorder or exacerbations of a pre-existing seizure disorder were seen following gastric bypass surgery in a retrospective case series of mor...
|
|
| |